BALL BRYAN 4

What Happened
Bryan Ball, Chief Technical Operations Officer and SVP, Manufacturing Operations at Whitehawk Therapeutics (WHWK), had 5,000 restricted stock units convert to 5,000 shares on March 1, 2026 (conversion of derivative/RSU). To satisfy tax withholding, 1,834 of those shares were broker-sold on March 2, 2026 at $3.31 each for a total of $6,070. Net shares retained from this vesting event: 3,166 (5,000 vested − 1,834 sold).

Key Details

• Transactions reported: conversion/vesting of 5,000 RSUs (coded M) on 2026-03-01; broker-assisted sale of 1,834 shares (coded S) on 2026-03-02 at $3.31/share for $6,070 total.
• Footnotes: F1 clarifies each RSU equals one share on vesting; F2 confirms the sale was broker-assisted to cover tax withholding; F3 outlines the RSU vesting schedule (25% annually from 3/1/2024).
• Filing: Form 4 filed 2026-03-10 (covers transactions dated Mar 1–2, 2026) — this appears to be later than the standard two-business-day Form 4 reporting window.
• Shares owned after the transaction were not specified in the provided excerpt; net newly retained shares from this event = 3,166.

Context

• This was a routine vesting of RSUs with a broker-assisted sale to satisfy tax withholding (common practice). The conversion was not a paid purchase (no cash outlay); the partial sale is not necessarily a signal about company outlook.
• Not a 10% owner transaction; this is an executive's compensation vesting and related tax-sale activity.